139 related articles for article (PubMed ID: 14725787)
1. ScFv-mediated in vivo targeting of DAF to erythrocytes inhibits lysis by complement.
Spitzer D; Unsinger J; Bessler M; Atkinson JP
Mol Immunol; 2004 Feb; 40(13):911-9. PubMed ID: 14725787
[TBL] [Abstract][Full Text] [Related]
2. Role of decay-accelerating factor in regulating complement activation on the erythrocyte surface as revealed by gene targeting.
Sun X; Funk CD; Deng C; Sahu A; Lambris JD; Song WC
Proc Natl Acad Sci U S A; 1999 Jan; 96(2):628-33. PubMed ID: 9892684
[TBL] [Abstract][Full Text] [Related]
3. Complement sensitivity of erythrocytes in a patient with inherited complete deficiency of CD59 or with the Inab phenotype.
Shichishima T; Saitoh Y; Terasawa T; Noji H; Kai T; Maruyama Y
Br J Haematol; 1999 Feb; 104(2):303-6. PubMed ID: 10050712
[TBL] [Abstract][Full Text] [Related]
4. Studies on the sensitivity to complement-mediated lysis of erythrocytes (Inab phenotype) with a deficiency of DAF (decay accelerating factor).
Merry AH; Rawlinson VI; Uchikawa M; Daha MR; Sim RB
Br J Haematol; 1989 Oct; 73(2):248-53. PubMed ID: 2479410
[TBL] [Abstract][Full Text] [Related]
5. Relationship between decay accelerating factor deficiency, diminished acetylcholinesterase activity, and defective terminal complement pathway restriction in paroxysmal nocturnal hemoglobinuria erythrocytes.
Medof ME; Gottlieb A; Kinoshita T; Hall S; Silber R; Nussenzweig V; Rosse WF
J Clin Invest; 1987 Jul; 80(1):165-74. PubMed ID: 2439544
[TBL] [Abstract][Full Text] [Related]
6. Decay-accelerating factor is present on paroxysmal nocturnal hemoglobinuria erythroid progenitors and lost during erythropoiesis in vitro.
Moore JG; Frank MM; Müller-Eberhard HJ; Young NS
J Exp Med; 1985 Oct; 162(4):1182-92. PubMed ID: 2413153
[TBL] [Abstract][Full Text] [Related]
7. The erythrocytes in paroxysmal nocturnal haemoglobinuria of intermediate sensitivity to complement lysis.
Rosse WF; Hoffman S; Campbell M; Borowitz M; Moore JO; Parker CJ
Br J Haematol; 1991 Sep; 79(1):99-107. PubMed ID: 1716964
[TBL] [Abstract][Full Text] [Related]
8. Protective effect of scFv-DAF fusion protein on the complement attack to acetylcholine receptor: a possible option for treatment of myasthenia gravis.
Song C; Xu Z; Miao J; Xu J; Wu X; Zhang F; Lin H; Li Z; Kaminski HJ
Muscle Nerve; 2012 May; 45(5):668-675. PubMed ID: 22499093
[TBL] [Abstract][Full Text] [Related]
9. Enhanced reactive lysis of paroxysmal nocturnal hemoglobinuria erythrocytes by C5b-9 does not involve increased C7 binding or cell-bound C3b.
Rosenfeld SI; Jenkins DE; Leddy JP
J Immunol; 1985 Jan; 134(1):506-11. PubMed ID: 3964820
[TBL] [Abstract][Full Text] [Related]
10. Sheep red blood cells armed with anti-CD20 single-chain variable fragments (scFvs) fused to a glycosylphosphatidylinositol (GPI) anchor: a strategy to target CD20-positive tumor cells.
Hamdy N; Goustin AS; Desaulniers JP; Li M; Chow CS; Al-Katib A
J Immunol Methods; 2005 Feb; 297(1-2):109-24. PubMed ID: 15777935
[TBL] [Abstract][Full Text] [Related]
11. Targeting of functional antibody-decay-accelerating factor fusion proteins to a cell surface.
Zhang H; Lu S; Morrison SL; Tomlinson S
J Biol Chem; 2001 Jul; 276(29):27290-5. PubMed ID: 11352906
[TBL] [Abstract][Full Text] [Related]
12. Implication of membrane factors other than DAF and CD59 in complement-mediated lysis of paroxysmal nocturnal hemoglobinuria erythrocytes.
Hatanaka M; Inai S; Matsumoto M; Miyagawa S; Masaoka T; Kanamaru A; Kawakita M; Yonemura Y; Sugita Y; Seya T
Clin Immunol Immunopathol; 1993 Oct; 69(1):52-9. PubMed ID: 7691453
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and biodistribution of genetically-engineered antibodies.
Colcher D; Pavlinkova G; Beresford G; Booth BJ; Choudhury A; Batra SK
Q J Nucl Med; 1998 Dec; 42(4):225-41. PubMed ID: 9973838
[TBL] [Abstract][Full Text] [Related]
14. Role of human decay-accelerating factor in the evasion of Schistosoma mansoni from the complement-mediated killing in vitro.
Horta MF; Ramalho-Pinto FJ
J Exp Med; 1991 Dec; 174(6):1399-406. PubMed ID: 1720809
[TBL] [Abstract][Full Text] [Related]
15. Human and rodent decay-accelerating factors (CD55) are not species restricted in their complement-inhibiting activities.
Harris CL; Spiller OB; Morgan BP
Immunology; 2000 Aug; 100(4):462-70. PubMed ID: 10929073
[TBL] [Abstract][Full Text] [Related]
16. Affected erythrocytes of patients with paroxysmal nocturnal hemoglobinuria are deficient in the complement regulatory protein, decay accelerating factor.
Nicholson-Weller A; March JP; Rosenfeld SI; Austen KF
Proc Natl Acad Sci U S A; 1983 Aug; 80(16):5066-70. PubMed ID: 6576376
[TBL] [Abstract][Full Text] [Related]
17. Classical pathway complement destruction is not responsible for the loss of human erythrocytes during porcine liver perfusion.
Rees MA; Butler AJ; Negus MC; Davies HF; Friend PJ
Transplantation; 2004 May; 77(9):1416-23. PubMed ID: 15167601
[TBL] [Abstract][Full Text] [Related]
18. Expression of human decay accelerating factor or membrane cofactor protein genes on mouse cells inhibits lysis by human complement.
White DJ; Oglesby T; Liszewski MK; Tedja I; Hourcade D; Wang MW; Wright L; Wallwork J; Atkinson JP
Transpl Int; 1992; 5 Suppl 1():S648-50. PubMed ID: 14621899
[TBL] [Abstract][Full Text] [Related]
19. Release of decay-accelerating factor (DAF) from the cell membrane by phosphatidylinositol-specific phospholipase C (PIPLC). Selective modification of a complement regulatory protein.
Davitz MA; Low MG; Nussenzweig V
J Exp Med; 1986 May; 163(5):1150-61. PubMed ID: 2422313
[TBL] [Abstract][Full Text] [Related]
20. Biocompatible coupling of therapeutic fusion proteins to human erythrocytes.
Villa CH; Pan DC; Johnston IH; Greineder CF; Walsh LR; Hood ED; Cines DB; Poncz M; Siegel DL; Muzykantov VR
Blood Adv; 2018 Feb; 2(3):165-176. PubMed ID: 29365311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
